February 1, 2021

ZebiAI and TB Alliance Announce Collaboration to Apply ML-Driven Discovery Platform to Tuberculosis Targets

TB Alliance to leverage ZebiAI’s platform to discover novel probe compounds for important tuberculosis targets, with options for drug discovery
January 28, 2021

New Report Reveals that R&D Partnerships Serving Neglected Communities have Produced Dozens of Life-Saving Innovations Since 2010

Novel approach for minimizing investment risks and stretching limited budgets has 375 innovations targeting infectious diseases under development
December 14, 2020

TB Alliance Announces First Patient Dosed with TBAJ-587 in Phase 1 Study

Study seeks to further develop a new compound to treat patients with tuberculosis
October 23, 2020

TB Alliance with the Support of the Republic of Korea Announce Initiative to Broaden Adoption and Scale Up of New Treatments for Drug-Resistant Tuberculosis (TB)

LIFT-TB to increase treatment completion rates for drug-resistant TB, focusing on seven high-burden Southeast and Central Asian countries that shoulder about 1 in 5 TB cases
August 3, 2020

TB Alliance Announces European Commission Authorisation of New Treatment for Highly Drug-Resistant Tuberculosis

Pretomanid, developed by the non-profit TB Alliance, has received EU marketing authorisation in combination regimen with bedaquiline and linezolid in adults with XDR-TB or treatment-intolerant/non-responsive MDR-TB

Pages